Quick Answer
Entrada Therapeutics, Inc. reported Net Income of -$143.75 million for fiscal year 2025.
Entrada Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$143.75M | -319.0% |
| 2024 | $65.63M | +1081.7% |
| 2023 | -$6.68M | +92.9% |
| 2022 | -$94.62M | -84.9% |
| 2021 | -$51.16M | -92.9% |
| 2020 | -$26.52M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$44.13M | -214.5% | -2.4% |
| June 30, 2025 | -$43.10M | -178.3% | -148.4% |
| March 31, 2025 | -$17.35M | -173.8% | -23.6% |
| September 30, 2024 | -$14.03M | -139.6% | -125.5% |
| June 30, 2024 | $55.03M | +312.2% | +134.2% |
| March 31, 2024 | $23.50M | +452.1% | -33.7% |
| September 30, 2023 | $35.46M | +241.1% | +236.8% |
| June 30, 2023 | -$25.93M | -11.9% | -288.5% |
- Entrada Therapeutics, Inc. showed a decrease of -319.0% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Entrada Therapeutics, Inc.’s net income has declined by 442.0% (from -$26.52 million to -$143.75 million).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: